MTCO2P20

Across TCGA pan-cancer cohorts, MTCO2P20 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of MTCO2P20’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where MTCO2P20 RNA is repressed in tumor relative to normal tissue. In most cancer types MTCO2P20 is over-expressed in tumor, although a few such as BRCA and KICH show the opposite, repressed pattern.

BRCA, HNSC, and KICH are the cancer types where MTCO2P20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTCO2P20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	−0.056	.001	6	view →
HNSC	All	IV	+0.050	.009	4	view →
KICH	All	All	−0.044	.003	3	view →
UCEC	All	All	+0.134	.012	2	view →
LUSC	All	II,III,IV	−0.106	.006	2	view →
KIRC	Female	IV	−0.066	.013	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

MTCO2P20–BRCA

Open the BRCA breakdown →